Anup Kasi

University of Kansas Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Eltanexor shows increased sensitivity to tumor-derived organoids compared with WT mouse small intestine organoids. A, Representative photos of Apc min/+ tumor–derived (tumoroids) and WT mouse small intestinal tissue–derived organoids. B, Representative photos of WT organoids treated with 200 nmol/L eltanexor for 72 hours. C, Representative photos of tumoroids treated with 200 nmol/L eltanexor for 72 hours. D, Tumoroids and WT organoids were treated with a dosage of 200 nmol/L eltanexor over 72 hours. Every 24 hours, the relative change in the surface area of each population was determined in ImageJ. The relative change is normalized to each population’s average surface area at hour 0. Values represent the mean of three individual experiments ± SEM. At least 50 organoids were measured at each time point under each treatment condition. A Student t test was used to statistically compare relative changes in surface area at each time point between control-treat and eltanexor-treated groups. E, Representative photos of both organoid populations that were treated with 400 nmol/L eltanexor for 72 hours. After 72 hours, each population was stained with 10 μg/mL of Hoechst and 10 μg/mL of PI. The organoids experiencing cell death will stain with PI. F, Tumoroids and WT organoids were treated with DMSO or 50 nmol/L, 100 nmol/L, 200 nmol/L, 400 nmol/L, and 800 nmol/L eltanexor for 72 hours. At 72 hours, the organoids were stained with 10 μg/mL of Hoechst and 10 μg/mL of PI. The graph represents the percentage of organoids from each population that was stained with PI under the various eltanexor dosages. The values represent the mean of three individual experiments ± SEM. A Student t test was used to statistically compare % PI-positive organoids in each treatment group between control-treat and eltanexor-treated groups. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.)

Year:

2025

XPO1 is overexpressed in colorectal cancer. A, Boxplot derived from Gene Expression Profiling Interactive Analysis showing colon adenocarcinoma (COAD) tissue compared with normal colon tissue. (The Cancer Genome Atlas data derived from the online website Gene Expression Profiling Interactive Analysis: gepia.cancer-pku.cnn/detail.php?gene=XPO1). Based on a one-way ANOVA statistical test, the change in XPO1 expression is not significant. B, XPO1 mRNA expression by qPCR in major colorectal cancer tumor stages normalized to normal colon tissue. Actin was used as the loading control, and values represent mean fold change ± SEM. For normal human colon tissue, n = 8; for stage I colorectal cancer tissue, n = 5; for stage II colorectal cancer tissue, n = 9; for stage III colorectal cancer tissue, n = 16; and for stage IV colorectal cancer tissue, n = 10. A Student t test was used to statistically compare each colorectal cancer–staged tissue group to the normal colon tissue group. C, XPO1 mRNA expression by qPCR in multiple colorectal cancer cell lines compared with normal colon tissue. GAPDH was used as the loading control, and values represent mean fold change ± SEM. A Student t test was used to statistically compare each cell line to normal human colon tissue group. D, Eltanexor structure and XPO1 structure highlighting eltanexor’s protein docking region in XPO1’s protein-binding groove. (PDB: 6XJT; *, P ≤ 0.05; ***, P ≤ 0.001; ****, P ≤ 0.0001). CRC, colorectal cancer.

Year:

2025

Eltanexor treatment reduces tumor burden and size in Apc min/+ mice. A, Representative photo of Apc min/+ mouse adenoma and adjacent normal colon IHC stained for XPO1. Nuclei are counterstained with hematoxylin. The “T” label on the tissue represents tumor tissue, and the “N” label represents normal tissue. The scale bars represent 200 μm. B, Seven mice received vehicle three times per week and seven mice received eltanexor three times per week at a dose of 10 mg/kg by oral gavage. Representative small intestine regions from Apc min/+ mice that received vehicle or eltanexor treatment. The tissue was fixed with 10% formalin and stained with 0.1% methylene blue. The arrows point to tumors present on the tissue. C, Total intestinal tumor burden of Apc min/+ mice that were treated from the age of 4 to 11 weeks with 10 mg/kg of eltanexor or vehicle 3×/week. The value represents the mean total intestinal tumor burden ± SEM of seven different mice. A Student t test was used to statistically compare tumor burden in vehicle-treated and eltanexor-treated mice. D, Frequency of ≤0.4 mm, 0.5 to 0.9 mm, and ≥1 mm tumors in the vehicle-treated and eltanexor-treated groups. E, Representative images and quantifications of vehicle-treated and eltanexor-treated tumors immunofluorescently stained for XPO1. Hoechst was used to stain the nucleus, and green represents the protein of interest. F, The quantifications are the mean fluorescent signal produced by an individual tumor. Three individual mice that received vehicle or eltanexor treatment were used in the quantification. The values represent the mean XPO1 fluorescence ± SEM. The scale bars represent 200 μm. A Student t test was used to statistically compare XPO1 protein expression in vehicle-treated and eltanexor-treated mice. G, Representative images and quantifications of vehicle-treated and eltanexor-treated tumors immunofluorescently stained for COX-2. Hoechst was used to stain the nucleus, and the green represents COX-2. H, The graph depicts the number of COX-2–positive cells per image. Three mice, vehicle treated or eltanexor treated, were used in the quantification. The scale bars represent 200 μm. A Student t test was used to statistically compare COX-2 protein expression in vehicle-treated and eltanexor-treated mice. A.U., arbitrary units. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.)

Year:

2025

Colorectal cancer is the second leading cause of cancer-related death in the United States and high-risk individuals face a notably higher likelihood of developing colorectal cancer based on their genetic background. Hence, there is a compelling need for innovative chemopreventive treatments aimed at minimizing colorectal cancer tumorigenesis. Exportin 1 (XPO1; also referred to as CRM1) plays a pivotal role in transporting proteins from the nucleus to the cytoplasm. Various cancers overexpress XPO1, including colorectal cancer, and selective inhibitors of nuclear export compounds, such as eltanexor (KPT-8602), have been developed to target XPO1. Eltanexor demonstrates fewer adverse effects than its precursors and is currently under evaluation in phase I/II clinical trials. This research evaluates eltanexor as a chemopreventive agent for colorectal cancer. Our findings indicate that eltanexor treatment inhibits expression of the common chemoprevention target in colorectal cancer, COX-2. This occurs by eltanexor-dependent reduction of Wnt/β-catenin signaling. Furthermore, XPO1 inhibition leads to forkhead transcription factor O subfamily member 3a nuclear retention, which can modulate β-catenin/TCF transcriptional activity. The in vivo oral treatment of eltanexor to Apc min/+ mice (a mouse model for familial adenomatosis polyposis) was well tolerated and reduced tumor burden by approximately threefold, along with decreased tumor size. Drug sensitivity assays using organoids from Apc min/+ mice tumors showed increased sensitivity to eltanexor compared with wild-type organoids. Collectively, these findings highlight XPO1 as a potent target for colorectal cancer chemoprevention. Significance: In this study, we show the XPO1 inhibitor eltanexor acts as an effective colorectal cancer chemopreventive agent both in vivo and in vitro . This occurs by reducing COX-2 expression by modulating the Wnt/β-catenin signaling pathway. Collectively, these findings highlight XPO1 as a potent target for colorectal cancer chemoprevention.

Year:

2025

Eltanexor reduces COX-2 expression. A and B, Western blot probing for COX-2 protein in HCA-7 cells treated with either control or 200 nmol/L eltanexor for 48 hours. Actin was used as the loading control. The graph depicts the quantified densitometry of the Western blot bands. The values have been normalized to the control-treated cells. The graph shows the mean of three independent experiments ± SEM. A Student t test was used to statistically compare COX-2 expression in the control-treated and eltanexor-treated groups. C, COX-2 mRNA expression by qPCR in HCA-7 cells treated with DMSO control or 200 nmol/L eltanexor for 48 hours. The values are the mean of four experiments ± SEM. A Student t test was used to statistically compare COX-2 expression in the control-treated and eltanexor-treated groups. D, HCT116 cells transfected with a plasmid containing the COX-2 promoter + luciferase gene. The cells were subsequently treated with 200 nmol/L eltanexor for 48 hours. The graph shows the mean eltanexor-treated luciferase activity/μg of protein normalized to DMSO-treated values of three independent experiments ± SEM. A Student t test was used to statistically compare luciferase activity in the control-treated and eltanexor-treated groups. E, HCT116 cells were transfected with COX-2 promoter + luciferase gene. The promoter region was deleted from full-length down to 300 base pairs. Cells were subsequently treated with DMSO (gray bars) or 200 nmol/L eltanexor (red bars) for 24 hours. The graph shows the mean luciferase activity/μg of protein of eltanexor-treated cells normalized to DMSO-treated values of three independent experiments ± SEM. A Student t test was used to statistically compare luciferase activity in the control-treated and eltanexor-treated groups. F, Schematic representation showing the site of COX-2 expression promotion by Wnt/β-catenin signaling. G and H, Western blot probing for c-myc in HCT116 cells treated with either control or 200 nmol/L eltanexor for 48 hours. The graph depicts the mean of c-myc band densitometry value normalized to actin of three independent experiments ± SEM. A Student t test was used to statistically compare c-myc expression in control-treated and eltanexor-treated groups. (*, P ≤ 0.05; **, P ≤ 0.01.). NS, not significant.

Year:

2025

Eltanexor increases FoxO3a nuclear localization to modulate Wnt/β-catenin signaling. A–C, HCT116, RKO, and DLD1 cells (all harboring different Wnt signaling phenotypes) were transfected with a TOPFlash reporter plasmid. Cells were subsequently treated with DMSO or eltanexor. RKO and HCT116 cells were treated with 200 nmol/L eltanexor, and DLD1 cells were treated with 400 nmol/L eltanexor for 24 hours. Luciferase activity/μg of protein was normalized to DMSO-treated luciferase expression for each respective cell line ± SEM. A Student t test was used to statistically compare luciferase activity in the control-treated and eltanexor-treated groups. D, HCT116 cells were treated for 48 hours with either 200 nmol/L eltanexor or DMSO. Subsequently, the cells were subject to immunofluorescent staining for FoxO3a (green). The nucleus was stained with DAPI (blue). E, The mean FoxO3a nuclear fluorescence for cells treated with DMSO (control) or 200 nmol/L eltanexor for 48 hours. The graph depicts the mean of three independent experiments ± SEM. At least 40 cells were analyzed for each independent experiment. The scale bars represent 50 μm. A Student t test was used to compare the mean fluorescence in the control-treated and eltanexor-treated groups. F and G, In HCT116 cells, FoxO3a was knocked down by siRNA. After knockdown, the cells were transfected with a TOPFlash reporter plasmid. The FoxO3a knockdown–transfected and TOPFlash-transfected cells were subject to immunoblotting to confirm FoxO3a knockdown. Actin was used as the loading control. The graph depicts the quantified densitometry of the Western blot bands. The values are normalized to actin and relative to control siRNA treated. The graph depicts the mean of three independent experiments ± SEM. A Student t test was used to statistically compare FoxO3a expression in the control siRNA–treated and FoxO3a siRNA–treated groups. H, The relative luciferase activity/μg of protein values was normalized to control siRNA. A Student t test was used to statistically compare luciferase activity in the control-treated and eltanexor-treated groups. The graph depicts the mean of three independent experiments ± SEM. A Student t test was used to statistically compare the control siRNA–treated and FoxO3a siRNA–treated groups. (*, P ≤ 0.05; **, P ≤ 0.01.)

Year:

2025

Eltanexor reduces XPO1 protein while reducing cell viability. A, Human colorectal cancer cell lines HCA7, HCT116, SW480, DLD-1, and RKO with varying concentrations of eltanexor. The cell survival was measured with CCK8 after incubation for 72 hours with eltanexor. The data represent the mean seven individual experiments ± SEM. The chart shows determined IC 50 values. B, Phase-contrast images showing HCT116 cells treated with varying dosages of eltanexor for 48 hours. C and D, HCT116 WT cells were injected into each of the subcutaneous dorsal flanks of athymic nude mice (two tumors/mouse). Measurements were taken 3× a week. Values graphed represent mean tumor volume ± SEM. Mice were either treated with 10 mg/kg eltanexor or the vehicle 3×/week. Representative images of tumors from the vehicle-treated and eltanexor-treated mice (vehicle treated n = 2 mice; eltanexor treated n = 3 mice). A Student t test was performed to statistically compare the vehicle-treated tumor volume to the eltanexor-treated tumor volume. E, Fluorescent microscopy images of HCT116 cells treated with control or 200 nmol/L eltanexor for 48 hours. Green represents XPO1, and DAPI was used to stain the nucleus. The scale bars represent 25 μm. F, Comparison of XPO1 fluorescent signal between control-treated and 200 nmol/L eltanexor-treated cells. The values graphed are the mean fluorescence values of three independent experiments ± SEM. At least 40 cells were quantified for each experiment. A Student t test was used to statistically compare the control-treated group fluorescence to the eltanexor-treated group fluorescence. G, Immunofluorescent detection of XPO1 in the vehicle- and eltanexor-treated tumors. Green represents XPO1 and Hoechst was used to stain the nucleus. Representative tissue sections were used and imaged at 20× magnification. The scale bars represent 200 μm. H , Comparison of XPO1 fluorescent signal between vehicle-treated and eltanexor-treated tumors. The values graphed are the mean fluorescence value of three xenograft tumors ± SEM. A Student t test was used to statistically compare XPO1 fluorescence in vehicle-treated and eltanexor-treated tumors. A.U., arbitrary units. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.)

Year:

2025

Colorectal cancer is the second leading cause of cancer-related death in the United States and high-risk individuals face a notably higher likelihood of developing colorectal cancer based on their genetic background. Hence, there is a compelling need for innovative chemopreventive treatments aimed at minimizing colorectal cancer tumorigenesis. Exportin 1 (XPO1; also referred to as CRM1) plays a pivotal role in transporting proteins from the nucleus to the cytoplasm. Various cancers overexpress XPO1, including colorectal cancer, and selective inhibitors of nuclear export compounds, such as eltanexor (KPT-8602), have been developed to target XPO1. Eltanexor demonstrates fewer adverse effects than its precursors and is currently under evaluation in phase I/II clinical trials. This research evaluates eltanexor as a chemopreventive agent for colorectal cancer. Our findings indicate that eltanexor treatment inhibits expression of the common chemoprevention target in colorectal cancer, COX-2. This occurs by eltanexor-dependent reduction of Wnt/β-catenin signaling. Furthermore, XPO1 inhibition leads to forkhead transcription factor O subfamily member 3a nuclear retention, which can modulate β-catenin/TCF transcriptional activity. The in vivo oral treatment of eltanexor to Apcmin/+ mice (a mouse model for familial adenomatosis polyposis) was well tolerated and reduced tumor burden by approximately threefold, along with decreased tumor size. Drug sensitivity assays using organoids from Apcmin/+ mice tumors showed increased sensitivity to eltanexor compared with wild-type organoids. Collectively, these findings highlight XPO1 as a potent target for colorectal cancer chemoprevention. Significance: In this study, we show the XPO1 inhibitor eltanexor acts as an effective colorectal cancer chemopreventive agent both in vivo and in vitro. This occurs by reducing COX-2 expression by modulating the Wnt/β-catenin signaling pathway. Collectively, these findings highlight XPO1 as a potent target for colorectal cancer chemoprevention.

Year:

2025

Supplementary Table S4: Comparison of cytokine gene expression between KRAS mutational subgroups. Median values represent transcript per million (TPM). Only genes with trending or significant differences between subgroups are shown. Bold numbers indicate trending (p

Year:

2025

Purpose: Oncogenic mutations in KRAS have been identified in >85% of pancreatic ductal adenocarcinoma (PDAC) cases, with G12D, G12V, and G12R being the most frequent variants. Using large clinical and genomic databases, this study characterizes prognostic and molecular differences between KRAS variants, focusing on KRAS G12D and KRAS G12R . Experimental Design: PDAC samples were tested using DNA and RNA sequencing. The MAPK activation score and tumor microenvironment were analyzed from RNA expression data. Real-world overall survival (OS) obtained from insurance claims data was calculated from tissue collection to last contact. Significance was determined by χ 2 and Fisher exact tests. Results: A total of 3,755 patients with PDAC harboring KRAS G12D ( n = 1,766), KRAS G12V ( n = 1,294), KRAS G12R ( n = 621), or KRAS G12C ( n = 74) variants were identified. Patients with G12R mutations had longer OS compared with those with G12D overall (12.7 vs. 10.1 months; P value = 0.0001), with similar trends in patients treated with gemcitabine/nab-paclitaxel (13.5 vs. 10.4 months; P value = 0.0002) or FOLFIRINOX (18.3 vs. 14.0 months; P value ARID1A and KMT2D mutations were more frequent in the G12D subgroup. Several genes involved in glucose and glutamine metabolism were less expressed in G12R compared with G12D. PD-L1 expression was lower in G12R compared with G12D (13% vs. 19%). Conclusions: KRAS G12D tumors exhibited a distinct molecular profile compared with G12R tumors, including genes involved in the MAPK pathway, immune activation, and glucose and glutamine metabolism. Patients with G12D mutations had lower OS compared with those with G12R. Based on these data, future studies should address the KRAS mutation status and explore distinct therapeutic vulnerabilities.

Year:

2025

Year:

2025

Year:

2023

Collaborators (5)

Michael Pishvaian

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

SANJAY GOEL

Rutgers University

UNITED STATES
View details

Jashodeep Datta

University of Miami

UNITED STATES
View details

Rachna Shroff

University of Arizona

UNITED STATES
View details